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Abstract
Background: Multiple sclerosis (MS) is an organ-specific autoimmune disease resulting in demyelinating plaques
throughout the central nervous system. In MS, the exact role of microglia remains unknown. On one hand, they can
present antigens, skew T cell responses, and upregulate the expression of pro-inflammatory molecules. On the
other hand, microglia may express anti-inflammatory molecules and inhibit inflammation. Microglia express a wide
variety of immune receptors such as nod-like receptors (NLRs). NLRs are intracellular receptors capable of regulating
both innate and adaptive immune responses. Among NLRs, Nlrp12 is largely expressed in cells of myeloid origins. It
plays a role in immune inflammatory responses by negatively regulating the nuclear factor-kappa B (NF-κB)
pathway. Thus, we hypothesize that Nlrp12 suppresses inflammation and ameliorates the course of MS.
Methods: We used experimental autoimmune encephalomyelitis (EAE), a well-characterized mouse model of MS.
EAE was induced in wild-type (WT) and Nlrp12−/− mice with myelin oligodendrocyte glycoprotein (MOG):complete
Freud’s adjuvant (CFA). The spinal cords of healthy and immunized mice were extracted for immunofluorescence
and pro-inflammatory gene analysis. Primary murine cortical microglia cell cultures of WT and Nlrp12−/− were
prepared with cortices of 1-day-old pups. The cells were stimulated with lipopolysaccharide (LPS) and analyzed for
the expression of pro-inflammatory genes as well as pro-inflammatory molecule secretions.
Results: Over the course of 9 weeks, the Nlrp12−/− mice demonstrated increased severity in the disease state,
where they developed the disease earlier and reached significantly higher clinical scores compared to the WT mice.
The spinal cords of immunized WT mice relative to healthy WT mice revealed a significant increase in Nlrp12
messenger ribonucleic acid (mRNA) expression at 1, 3, and 5 weeks post injection. A significant increase in the
expression of pro-inflammatory genes Ccr5, Cox2, and IL-1β was found in the spinal cords of the Nlrp12−/− mice
relative to the WT mice (P < 0.05). A significant increase in the level of gliosis was observed in the spinal cords of
the Nlrp12−/− mice compared to the WT mice after 9 weeks of disease (P < 0.05). Primary Nlrp12−/− microglia cells
demonstrated a significant increase in inducible nitric oxide synthase (iNOS) expression (P < 0.05) and secreted
significantly (P < 0.05) more tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and nitric oxide (NO).
Conclusion: Nlrp12 plays a protective role by suppressing inflammation during the development of EAE. The
absence of Nlrp12 results in an increased inflammatory response.
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Background
Multiple sclerosis (MS) is among one of the most com-
mon neurodegenerative diseases affecting an estimated
2.3 million individuals worldwide [1]. This organ-specific
autoimmune disease is characterized by four different
types of demyelinating plaques; types I and II which are
T cell mediated or T cell and antibody-mediated, while
types III and IV are mediated by oligodendrocyte death
[2]. In all four cases, plaques are associated with acti-
vated macrophages, microglia, and astrocytes.
Regardless of the type of plaque formation, inflamma-
tion plays a central role in MS pathophysiology [1, 3].
Microglia, the resident immune cells of the central
nervous system (CNS), play a major role in maintaining
CNS homeostasis. They have been shown to be associ-
ated with developing plaques and are thought to contrib-
ute to the development of MS [2, 4], as well as other
chronic inflammatory neurodegenerative diseases such
as Alzheimer’s [5]. During MS, activated microglia can
play the role of antigen-presenting cells (APCs) and,
therefore, skew T cell responses towards a T helper cell
1 (Th1) pro-inflammatory phenotype [1, 2, 6]. In
addition, once activated, microglia upregulate the ex-
pression of pro-inflammatory molecules including but
not restricted to tumor necrosis factor alpha (TNFα),
interleukin (IL)-1β, IL-6, macrophage inhibitory protein
1 alpha (MIP1α), and inducible nitric oxide synthase
(iNOS), all of which have been shown to play a role in
demyelination and neuronal damage [7].
There is a wide variety of immune receptors expressed by
microglia that regulate its function. Pathogen-recognition
receptors (PRRs) such as nod-like receptors (NLRs) are in-
nate immune receptors and sensors of pathogen-associated
molecular patterns (PAMPs) [8]. NLRs are a group of pro-
teins that share a NACHT and leucine-rich repeat (LRR)
domain but differ in their N-terminal effector domain.
Upon recognition of their respective ligand, NLRs become
activated and it result in the subsequent triggering of mul-
tiple pro-inflammatory molecular pathways, such as nuclear
factor-kappa B (NF-κB). In addition, they are able to regu-
late both innate and adaptive immune responses and play a
role in pathological processes [8]. Recently discovered
Nlrp12 is a pyrin-containing intracellular NLR protein. It is
largely expressed in the cells of myeloid origin such
as monocytes and dendritic cells (DCs). The expres-
sion of Nlrp12 has been shown to play an important
role in immune inflammatory responses by negatively
regulating the NF-κB pathway and modulatory roles,
such as dendritic cell migration [9, 10]. The NF-κB
pathway is one of the major pathways involved in the
inflammatory response. Typically, the activation of
NF-κB following insults results in the transcription of
pro-inflammatory cytokines such as TNFα, IL-1β, and
IL-6; chemokines such as CCL5, CCL22, and MIP1α;
and proteins, such as iNOS and cyclooxygenase 2
(COX2) [11, 12].
This study aims to investigate the role of NLRs in neu-
roinflammation, particularly to uncover the role of
Nlrp12 during experimental autoimmune encephalomy-
elitis (EAE) development. In our study, results show that
Nlrp12 acts to downregulate inflammation during the
development of EAE. This study may have significant
implications in the development of potential novel ther-




Nlrp12 knock-out (Nlrp12−/−) mice were kindly provided
by Dr. Jenny P. Y. Ting (Chapel Hill, NC). All of the pro-
tocols and procedures were approved by the University
of Sherbrooke at the University of Sherbrooke Animal
Facility and Use Committee.
Experimental autoimmune encephalomyelitis
EAE was induced in 8–10-week-old C57BL/6 female
mice using a previously established protocol by Miller et
al. [13]. Briefly, a 1:1 emulsion mixture of myelin oligo-
dendrocyte glycoprotein (MOG35−55) (Genemed Synthe-
sis Inc., San Antonio, TX) and complete Freund’s
Adjuvant (CFA) (Sigma-Aldrich, St. Louis, MO) supple-
mented with 100 μg Mycobacterium tuberculosis H37
RA (Difco Laboratories, Detroit, MI) was prepared using
a glass tuberculin syringe. The MOG:CFA emulsion
(100 μL) was injected subcutaneously on each side of
the midline on the lower back of each mouse for a total
of 200 μg MOG35–55 and 500 μg Mycobacterium. Pertus-
sis toxin (200 ng) (List Biological Laboratories Inc.,
Campbell, CA) was injected intraperitoneally on the day
of and 48 h following immunization. The mice were
monitored every day for the development of disease.
Clinical scores were given by two independent observers,
using the following scale: 0, no sign of disease; 1, limp
tail or weakness in limbs; 2, limp tail and weakness in
limb; 3, partial limb paralysis; 4, complete limb paralysis.
Histopathology
The immunized mice were anesthetized by intraperitoneal
injection of Avertin® (2,2,2-tribromoethanol, approximately
240 mg/kg) (Sigma-Aldrich, St. Louis, MO) diluted in 0.9 %
saline solution. The mice were then perfused with ice-cold
phosphate-buffered saline (PBS) (Wisent, St. Bruno, QC),
and the spinal cords were removed and stored at −80 °C
immediately for RNA extraction (thoracic region) and
placed in 4 % paraformaldehyde (Sigma-Aldrich, St. Louis,
MO) for immunofluorescence analysis (lumbar region).
The spinal cord tissues were embedded in paraffin and cut
into 5-μm sections.
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T cell proliferation assay
T cell proliferation was performed using 3H-thymidine
incorporation assay. A single cell suspension was pre-
pared from draining the lymph nodes (more precisely,
from the inguinal and axillary lymph nodes) and spleen.
CD4+ T cells were then purified using EasySep Mouse
CD4+ T Cell Isolation Kit (Stem cell, Vancouver, BC),
seeded in a round-bottom 96-well culture plate (1 × 105
cells/well) and activated with plate-bound anti-CD3
(1 μg/mL) and anti-CD28 (2 μg/mL) antibodies for
3 days. During the last 18 h of culture, 1 μCi of methyl-
[3H]-thymidine (NEN Life Sciences, Boston, MA) was
added per well. The cells were harvested onto glass fiber
filter mats, and the incorporated radioactivity was mea-
sured using Top Count® microplate scintillation counter
(PerkinElmer, Wellesley, MA).
Intracellular IL-4 staining for flow cytometry
The purified CD4+ T cells from the wild-type (WT) and
Nlrp12−/− mice were activated by plate-bound anti-CD3
(1 μg/mL) and anti-CD28 (2 μg/mL) antibodies for
3 days. Then, the cells were stimulated with phorbol 12-
myristate 13-acetate (PMA; 50 ng/mL, Sigma Chemical
Co., St. Louis, MO) and ionomycin (1 μg/mL, Calbiochem
Corp., La Jolla, CA) for 4 h at 37 °C and 5 % CO2 in the
presence of Brefeldin A (1 μg/mL, eBioscience, San Diego,
CA). After staining the cells with anti-CD4-FITC antibody
(eBioscience), the cells were fixed and permeabilized
using intracellular fixation and permeabilization buffer
(eBioscience) and stained with anti-IL-4-PE antibody,
as per the manufacturer’s instructions. Sample ana-
lysis was performed with FACSCalibur, and data ana-
lysis was done using FlowJo Software (FlowJo, LLC,
Ashland, OR).
RNA extraction, cDNA synthesis, reverse transcription and
real-time quantitative PCR
RNA from the spinal cords and lymph nodes were ex-
tracted using TRIzol reagent (Life Technologies Inc.,
Burlington, ON). The tissues were homogenized with
sterile beads (Qiagen, Limburg, Netherlands) at a speed
of 20 Hz for 2 min. Chloroform (200 μL) (Fisher Scien-
tific, Ottawa, ON) was added to each tube per 1 mL of
TRIzol and incubated at room temperature for 15 min
followed by centrifugation at 13,000 rpm for 15 min at
4 °C. Supernatants were collected in new tubes, and
500 μL isopropanol (Fisher Scientific, Ottawa, ON) was
added to each tube and incubated for 10 min at −80 °C
before spinning down at 13,000 rpm for 10 min at 4 °C.
Pellets were washed with 75 % ethanol and re-suspended
in 20 μL RNAse-free sterile water (Wisent, St-Bruno, QC).
cDNA was synthesized using Oligo(dT) primer (IDT,
Coralville, IA), PCR Nucleotide Mix (GE Healthcare, Baie
d’Urfe, QC), M-MuLV Reverse Transcriptase, M-MuLV
Reverse Transcriptase Buffer (New England BioLabs,
Whitby, ON), and RNasin Ribonuclease Inhibitor
(Promega, Madison, WI). Reverse transcription PCR
(RT-PCR) and quantitative reverse transcription PCR
(RT-qPCR) were used to verify the expression of Nlrp12,
Mip3α, Cox2, IL-1β, and Ccr5 using Brilliant III Ultra-Fast
SYBR Green QPCR Master Mix (Agilent Technologies,
Santa Clara, CA). Primers (IDT, Coralville, IA) sequences
were as follows: Nlrp12 F: 5′-CCT CTT TGA GCC AGA
CGA AG-3′, Nlrp12 R: 5′-GCC CAG TCC AAC ATC
ACT TT-3′, Mip3α F: 5′-CTC AGC CTA AGA GTC
AAG AAG ATG-3′, Mip3α R: 5′-AAG TCC ACT GGG
ACA CAA ATC-3′, Cox2 F: 5′-CCA GCA CTT CAC
CCA TCA GTT-3′, Cox2 R: 5′-ACC CAG GTC CTC
GCT TAT GA-3′, IL-1β F: 5′-CAT CCA GCT TCA AAT
CTC GCA G-3′, IL-1β R: 5′CAC ACA CCA GCA GGT
TAT CAT C-3′, Ccr5 F: 5′-CGA AAA CAC ATG GTC
AAA CG-3′, Ccr5 R: 5′-GTT CTC CTG TGG ATC GGG
TA-3′, 18S F: 5′-CGG CTA CCA CAT CCA AGG AA-3′,
and 18S R: 5′-GCT GGA ATTACC GCG GCT-3′.
The samples were normalized to the internal control
18S rRNA, and relative expression was calculated using
the ΔΔCT method [14].
Immunofluorescence
Slides were de-paraffinized in xylene (EMD Millipore, Eto-
bicoke, ON) and hydrated in 100, 95, and 70 % ethanol gra-
dient. Antigen unmasking was performed at sub-boiling
temperature for 10 min in 10 mM sodium citrate buffer pH
6.0 (Sigma-Aldrich, St. Louis, MO). Immunofluorescence
was performed in Sequenza Slide Rack and Coverplate
System (Ted Pella, Inc., Redding, CA). The slides
were washed with 0.1 % Triton X-100 in PBS solu-
tion, blocked in 5 % fetal bovine serum (FBS) plus
0.1 % Triton X-100 in PBS for 1 h and incubated
with primary antibody (1:1000) overnight at 4 °C. Sec-
ondary antibody (1:2000) incubation was done at
room temperature for 2 h. The slides were mounted
with DAPI Fluoromount-G (SouthernBiotech, Bir-
mingham, AL), and photomicrograph pictures were
taken with Retiga SRV Mono Cooled numerical cam-
era attached to Zeiss Axioskop 2 Microscope. The
pictures were stitched with Adobe Photoshop CS6,
and stain density was quantified with Image-Pro Plus
6.0 (Media Cybernetics, Inc., Rockville, MD).
Antibodies
Rabbit anti-glial fibrillary acidic protein (GFAP) antibody
was purchased from Cedarlane (Burlington, ON). Rabbit
anti-ionized calcium-binding adaptor molecule 1 (Iba1)
antibody was purchased from Wako (Osaka, Japan). Alexa
Fluor 488 AfinniPure Goat Anti-Rabbit IgG (H + L) was
purchased from Jackson ImmunoResearch Laboratories
Inc. (West Grove, PA).
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The percentage of microgliosis and astrogliosis in the
spinal cord and gray matter were calculated as follows:
Percentage of gliosis %ð Þ ¼ Density stain
Total area
 100
The percentage of microgliosis and astrogliosis in the
white matter were calculated as follows:
Percentage of gliosis in the white matter %ð Þ
¼ Density stain of spinal cord−Density stain of gray matter




Cortices from 1-day-old pups were extracted and placed
onto a 100-mm petri dish using aseptic techniques. Cor-
tices were sliced with a commercial razor blade, further
broken up with a rigorous up-and-down motion in
10 mL of medium, and filtered with a 70-μm filter. The
cells were then plated onto a 100-mm petri dish and put
in an incubator of 37 °C with 5 % CO2. Cell culture
medium DMEM/F12 (Wisent, St. Bruno, QC) was sup-
plemented with 10 % FBS (Invitrogen, Burlington, ON),
1 % penicillin-streptomycin solution (Wisent, St-Bruno,
QC), 1 % L-glutamine solution (Wisent, St. Bruno, QC),
0.9 % sodium pyruvate solution (Wisent, St. Bruno, QC),
0.9 % MEM amino acid solution (Wisent, St. Bruno,
QC), and 0.9 % amphotericin B solution (Wisent, St.
Bruno, QC). The medium of the mixed glial culture was
changed every 2 to 3 days. After 3 weeks, primary
microglia cells were separated from astrocytes using
EasySep CD11b positive selection kit following the man-
ufacturer’s instructions (Stem cell, Vancouver, BC).
Immunoblotting
Proteins were separated in 10 % polyacrylamide gels and
transferred onto PVDF (Millipore, Etobicoke, ON) mem-
branes. The membranes were blocked with PBS contain-
ing 10 % nonfat milk and 0.05 % Tween-20 (Sigma-
Aldrich, St. Louis, MO). The membranes were washed
in 1× Tris-buffered saline (TBS) plus 1 % Tween-20 for
15 min and incubated with primary antibody (1:1000)
overnight at 4 °C and with secondary antibody (1:2000)
for 2 h at room temperature. The membranes were re-
vealed with GE HealthCare Life Sciences Amersham
ECL Plus (Baie d’Urfe, QC) and viewed with Molecular
Imager VersaDoc from BioRad, and protein bands were
quantified using NIH ImageJ software. The antibodies
used were as follows: β-actin (rabbit), iNOS (rabbit), and
anti-rabbit IgG HRP-linked antibodies were purchased
from Cell Signaling Technology (Beverly, MA).
Cytokine measurement
TNFα and IL-6 cytokines in the supernatant of microglia
culture were measured using ELISA kits purchased from
BioLegend (San Diego, CA). Cerebellum and lymph
node samples were homogenized in 0.5 mL of ice-cold
lysis buffer (Cell Signaling Technology, Beverly, MA)
supplemented with protease inhibitors (Roche Diagnosis,
Mannheim, Germany) by rapid agitation for 2 min in
the presence of 3-mm stainless beads. The tissue lysate
was centrifuged for 10 min at 13,000×g in a cold micro-
fuge, and the supernatant was transferred to a new tube.
The concentration of proteins in the lysate was deter-
mined by Bradford protein assay. The tissue levels of IL-
4 were determined using a high sensitivity IL-4 ELISA
Kit (eBioscience, San Diego, CA), and the concentration
of IL-4 in serum samples was quantified using Mouse
IL-4 DuoSet (R&D Systems), according to the manufac-
turer’s instruction.
Statistical analysis
All statistical analyses were conducted using GraphPad
Prism 6 software. The results were expressed as mean ±
SD. Statistical significance was determined using one-way
ANOVA Kruskal-Wallis followed by Bonferroni (EAE
clinical score), one-way ANOVA followed by Tukey-
Kramer (Nlrp12 mRNA expression, iNOS expression in
primary microglia, concentration of pro-inflammatory cy-
tokines), two-way ANOVA followed by Tukey’s (percent-
age of gliosis), or one-way ANOVA followed by Dunet
(pro-inflammatory mRNA expression) multiple compari-
son test. IL-4 results were compared between WT and
Nlrp12−/− mice using Mann-Whitney U test. Statistical
significance was accepted at P < 0.05.
Results
Nlrp12 mRNA expression reaches a peak at the third week
post injection
Following immunization with ovalbumin and MOG35–55
in CFA, the spinal cords were dissected from healthy
and EAE mice and analyzed for the expression of Nlrp12
messenger ribonucleic acid (mRNA) (Fig. 1). Nlrp12
mRNA expression in the immunized mice was shown to
be significantly increased relative to the healthy wild-
type (WT) mice at week 1 (threefold increase), week 3
(sevenfold increase), and week 5 (fourfold increase).
Additionally, the level of Nlrp12 mRNA expression was
increased as of the first week of EAE and reached its
highest level at the third week. At 5 weeks post injection,
although the expression of Nlrp12 was significantly
higher in the diseased mice compared to the healthy
mice, it was considerably lower than the third week and
resembled much more the disease state of the first week.
As a control, ovalbumin was injected, and the spinal
cords of the mice treated with ovalbumin were removed
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after the third week in order to keep consistency with
MOG-injected mice.
Nlrp12−/− mice exhibit exacerbated form of the disease
compared to WT mice
In order to investigate the role of Nlrp12 in MS, EAE was
induced in 8–10-week-old C57BL/6 female mice. An
emulsified mixture of MOG35–55 in CFA was subcutane-
ously injected in mice. The Nlrp12−/− mice demonstrated
clinical symptoms after approximately 5 days post injec-
tion whereas the WT mice developed the disease roughly
after 9 days. In addition, while the WT mice were showing
the first signs of disease, the Nlrp12−/− mice already dem-
onstrated indications of severe disease, reaching scores of
2, indicative of tail and back limb weaknesses (Fig. 2). In-
deed, the Nlrp12−/− mice were observed to reach higher
clinical scores throughout the 9-week period. More pre-
cisely, they reached scores of 3–3.5, which indicates weak-
ness in the tail, back, and front limbs compared to the
WT mice that reached scores of 2–2.5. In both genotypes,
the severity of the disease outcome was observed to peak
around the third week post injection and remained rela-
tively constant throughout the 9-week period.
Nlrp12−/− mice demonstrate higher percentage of reactive
gliosis after EAE
In response to injury, glial cells become reactive, produ-
cing multiple pro-inflammatory proteins, as well as in-
creasing in numbers. GFAP is an intermediate protein
expressed and upregulated by astrocytes in response to
CNS insults [15]. Moreover, in addition to the secretion
of multiple pro-inflammatory proteins, the reactive
microglial response can be measured by the extent of
upregulation of Iba1 [5]. The spinal cords of the healthy
and immunized mice were extracted and stained for
GFAP (Fig. 3) and Iba1 (Fig. 4). We observed no signifi-
cant difference in the percent level of astrogliosis and
microgliosis between the healthy WT and healthy
Nlrp12−/− mice. Additionally, we observed no differences
in the percentage of neither microgliosis nor astrogliosis
between the WT and Nlrp12−/− mice after 3 weeks of
EAE (Figs. 5a, 6a). However, after 9 weeks of disease, the
Nlrp12−/− mice demonstrated a significant increase in
the level of astrogliosis (30 % compared to 15 % in WTs)
in the white matter (WM) and an observable increase
within the gray matter (GM) area of the spinal cord
compared to the WT mice (Fig. 5b). The 10 % difference
between the Nlrp12−/− mice and the WT mice occurred
within the WM. Similar results were obtained for the
level of microgliosis, where the Nlrp12−/− mice demon-
strated increased percentage of Iba1 compared to the
WT mice (Fig. 6b). Indeed, the difference of 20 % in-
crease in microgliosis within the spinal cord of the
Nlrp12−/− mice compared to the WT mice was primarily
within the WM.
Nlrp12 negatively regulates T cell proliferation
We observed higher proliferation in responses to puri-
fied CD4+ T cells from the Nlrp12−/− compared to the
WT mice (Fig. 7a–c). Interestingly, while pure activation
by anti-CD3/CD28 antibodies resulted in the signifi-
cantly higher proliferative responses in T cells (Fig. 7c)
from the Nlrp12−/− compared to the WT mice, more
physiological activation by splenocytes, although, tended
to be higher in T cells from the Nlrp12−/− mice, did not
result in a statistically different proliferation compared






























Fig. 1 Nlrp12 mRNA expression reaches a peak at third week post
injection. Results indicate fold change in Nlrp12 mRNA expression of
the diseased mice over the healthy mice. The mice injected with
ovalbumin as control were sacrificed 3 weeks post injection. Results
are expressed as mean ± SD. Statistical significance was accepted at
*P < 0.05. Statistical analysis was done using one-way ANOVA
followed by Tukey-Kramer multiple comparison test. n = 5

















Fig. 2 Nlrp12−/− mice exhibit an exacerbated form of disease
compared to WT mice. Animals were scored daily by two independent
observers and scored based on the following scale: 0, no sign of
disease; 1, limp tail or weakness in limbs; 2, limp tail and weakness in
limbs; 3, partial limb paralysis; and 4, complete limb paralysis. Statistical
significance was accepted at *P < 0.05. Statistical analysis was done by
Kruskal-Wallis one-way ANOVA test followed by Bonferroni multiple
comparison test. n = 7
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Nlrp12 deficiency did not affect IL-4 production by
activated T cells
Differences in T cells proliferation prompted us to verify
the levels of IL-4 in the Nlrp12−/− mice after EAE induc-
tion. We chose to look at IL-4 in light of the recent publi-
cation by Lukens et al. that observed that Nlrp12 inhibited
Th2 responses. We investigated whether Nlrp12 defi-
ciency might affect IL-4 production by T cells in EAE
mice. As shown in Fig. 8a, no significant difference was
detected between the Nlrp12−/− and WT mice in the per-
centage of CD4+ IL-4+ T cells after 3 days of activation
with anti-CD3/CD28 antibodies in vitro. Consistent with
this finding, we did not observe any significant differences
in the levels IL-4 in lysates from the lymph nodes of the
Nlrp12−/− or WT EAE mice neither by RT-PCR (Fig. 8c)
nor by ELISA (Fig. 8e). Similar observation demonstrated
that there was no statistical difference between IL-4 levels
in serum (Fig. 8b) and cerebellum (Fig. 8d) from the
Nlrp12−/− EAE mice compared to the WT EAE mice.
Nlrp12 deficiency augments expression of pro-
inflammatory molecules in the CNS after EAE
Looking into the mechanisms of increased inflammation
in the Nlrp12−/−mice, we analyzed mRNA expression of
pro-inflammatory proteins in the spinal cords of the
mice 3 weeks post immunization (Fig. 9). Compared to
the WT mice, the Nlrp12−/− mice demonstrated signifi-
cantly higher levels of Cox2 (threefold increase), IL-1β
(fourfold increase), and Ccr5 (tenfold increase) mRNA
expressions. Although a relative increase in the mRNA
expression of Mip3α was observed, that difference was
not significant. Thus, these results demonstrate that in
the absence of Nlrp12, the inflammatory response is
much more significant.
Nlrp12−/− primary microglia express increased levels of
reactive species and pro-inflammatory cytokines
The inflammatory response is an important feature of
the innate immunity in the regulation of homeostasis.
Fig. 3 Photomicrograph pictures of the spinal cords stained with GFAP. GFAP staining of the spinal cord, evaluating astrogliosis percentage
following EAE induction. a WT mice, healthy. b Nlrp12−/− mice, healthy. c WT mice, 3 weeks EAE. d Nlrp12−/− mice, 3 weeks EAE. e WT mice,
9 weeks EAE. f Nlrp12−/− mice, 9 weeks EAE. Scale bar is 500 μm
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Fig. 4 Photomicrograph pictures of the spinal cords stained with Iba1. Iba1 staining of the spinal cord, evaluating microgliosis percentage
following EAE induction. a WT mice, healthy. b Nlrp12−/− mice, healthy. c WT mice, 3 weeks EAE. d Nlrp12−/− mice, 3 weeks EAE. e WT mice,
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Fig. 5 Percent level of astrogliosis following EAE. Percentage of astrogliosis is calculated by the intensity of GFAP staining on total area of the
spinal cord. a After 3 weeks EAE. b After 9 weeks EAE. Results are expressed as mean ± SEM. Statistical significance was accepted at *P < 0.05.
Statistical analysis was done by two-way ANOVA followed by Tukey’s multiple comparison test. Each spinal cord was quantified in duplicates
and/or triplicates. n = 3–4
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Inflammation is an innate response that occurs following
the encounter of harmful bodies; however, a shift to-
wards anti-inflammatory environment occurs in order to
re-establish the balance. Microglia cells play a critical
role in this process. Cortices from 1-day-old murine
pups were removed, and after 3 weeks in culture, pri-
mary microglia cells were separated from astrocytes.
Stimulation with bacterial endotoxin lipopolysaccharide
(LPS) revealed a significant increase (twofold increase)
in the expression of inducible nitric oxide synthase
(iNOS), the enzyme responsible for the production of ni-
tric oxide (NO), in Nlrp12−/− microglia compared to
WT microglia (Fig. 10a, b). The supernatants, following
LPS stimulation, were further analyzed by Griess reagent
assay, and we observed significantly more (2.5-fold in-
crease) nitrates secreted in the media from the microglia
of the Nlrp12−/− mice compared to the WT mice. We
additionally observed a dose-response effect (Fig. 10c).
To further characterize microglial response, purified
microglia from both genotypes were incubated with
500 ng/mL LPS for 12 h and supernatants were analyzed
for the presence of pro-inflammatory cytokines TNFα
and IL-6. At basal level, we observed no differences be-
tween the WT and Nlrp12−/− microglia. However, after
treatment with LPS, the microglia from the Nlrp12−/−
mice secreted more than twofold increase in TNFα
(Fig. 11a) and IL-6 (Fig. 11b) concentrations compared
to the WT microglia. Once again demonstrating that in
the absence of Nlrp12, the cellular environment is more
inflammatory.
Discussion
The process of inflammation is a fundamental response
aimed at protecting the body from foreign and detri-
mental causes. Neuroinflammation can become harmful
if it is unregulated and prolonged. A continuous and
WT Healthy
WT 3 weeks EAE
Nlrp12-/- Healthy












































Fig. 6 Percent level of microgliosis following EAE. Percentage of microgliosis is calculated by the intensity of Iba1 staining on the total area of
the spinal cord. a After 3 weeks EAE. b After 9 weeks EAE. Results are expressed as mean ± SEM. Statistical significance was accepted at *P < 0.05.
Statistical analysis was done by two-way ANOVA followed by Tukey’s multiple comparison test. Each spinal cord was quantified in duplicates




























Fig. 7 The proliferation of activated T cells from the WT and Nlrp12−/− mice in vitro. a, b CD4+ T cells were stained with CFSE and activated with
plate-bound anti-CD3/CD28 antibodies stimulation for 3 days. The intensity of CFSE dye in the cells was analyzed by flow cytometry. No significant
difference was observed. c Purified CD4+ T cells from the WT and Nlrp12−/− mice were stimulated with anti-CD3/CD28 for 72 h, and the incorporation
of 3H-thymidine was measured during the final 18 h of cell culture. Statistical significance was accepted at *P < 0.05. Statistical analysis was done by
Mann-Whitney U test, n = 3–6 per group
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persistent response will eventually lead to a chronic state
of inflammation, a prominent feature of many neurode-
generative diseases, including MS. NLRP12 is of interest
to the study of MS notably due to its restricted expres-
sion in cells derived from hematopoietic origins such as
monocytes, dendritic cells, and granulocytic cells, and
most recently, T cells [16] and its role in attenuating the
inflammatory response by interfering in both branches
of the NF-κB pathway [9, 17].
To investigate the implication of Nlrp12 in MS, EAE
was induced in the WT and in Nlrp12−/− mice. Our re-
sults demonstrated that in mice lacking the Nlrp12 gene,
EAE developed earlier compared to the WT mice, and
the Nlrp12−/− mice showed increased severity throughout
the course of the disease. Interestingly, after EAE induc-
tion, Nlrp12 mRNA expression was significantly increased
in the WT mice compared to the healthy WTs. These re-
sults suggest that Nlrp12 plays an important role in main-
taining the level of inflammation and ensuring that a
hyper-inflammatory state does not occur. In fact, the ex-
pression profile of Nlrp12 over the course of the disease is
suggestive of this regulatory role. Indeed, previous studies
have shown that in response to live bacteria such as M.
tuberculosis, TNFα, and IFNγ, a reduction in Nlrp12’s
expression is in accordance with an increase in the
inflammatory response [18, 19]. Moreover, Nlrp12’s over-
expression has been previously shown to attenuate the in-
flammatory response by negatively regulating the NF-κB
Fig. 8 IL-4 production by activated T cells from the WT or Nlrp12−/− mice in vitro and in vivo. a CD4+ T cells were purified from the lymph nodes
and spleens and stimulated with anti-CD3/CD28 antibodies. Intracellular production of IL-4 by activated CD4+ T cells was determined using flow
cytometry. b The levels of IL-4 in serum samples from WT and Nlrp12−/− EAE mice, measured by ELISA. c The level of IL-4 mRNA in lymph nodes
from WT and Nlrp12−/− EAE mice, quantified by real-time PCR. d, e The levels of IL-4 in tissue samples from the WT and Nlrp12−/− EAE mice. Cerebellum
and lymph node tissues were collected from the mice after 3 weeks of immunization with MOG:CFA. The tissues were homogenized in lysis buffer,
and IL-4 levels were measured in tissue lysate by ELISA. Statistical analysis was done by Mann-Whitney U test, n = 3–6 per group. No
significant difference was observed
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pathways [17]. A study conducted by Shami et al. demon-
strated that the expression of Nlrp12 is increased in re-
sponse to nitric oxide [20]. NO is a reactive molecule that
is produced in iNOS at sites of inflammation in MS, and it
is involved in lesion development [21]. As T cell responses
play a crucial role in the development of EAE [12], we
evaluated purified CD4 T cell proliferative response after
CD3/CD28 activation and we saw significantly elevated
proliferation of T cells from the Nlrp12−/− mice. We then
evaluated Tcells proliferation using recall response 10 days
after EAE induction by stimulating purified CD4 T cells
with MOG peptide in the presence of splenocytes. We ob-
served the tendency of T cells from the Nlrp12−/− mice for
a higher proliferation rate; however, these differences
never reached a statistical significance. These results are
similar to those published by Lukens et al. [16], where
authors observed that pure anti-CD3/CD 28 activation
resulted in significantly higher proliferation in T cells
from Nlrp12−/− mice, while in the presence of spleno-
cytes, differences between T cell proliferation of differ-
ent genotypes were greatly reduced. In this work, the
authors propose that the cell autonomous effect of
Nlrp12 in T cells shifts T cell differentiations to a Th2-
IL-4 producing phenotype [16].
We measured the concentration of IL-4 in the serum,
lymph nodes, and brain samples from the WT and from
Nlrp12−/− mice at 3 weeks after EAE and did not find
any differences in the expression of IL-4. These results
are consistent with our observation that there were no
differences in percentage of IL-4 producing cells and
that results from experiments in complex cellular inter-
action at the tissue level in vivo can be different from
results of clean anti-CD3/CD28 activation in vitro. Till
today, no exact mechanism has been described that ex-
plains Nlrp12 activity in different cell types. Nlrp12 has
been shown to inhibit classical and alternative pathways
of NF-κB in different cell types and different stimulations;
for extensive review, please read Tuncer et al. [9]. In light
of these controversies, the different KO strategies to re-
move Nlrp12 may have produced an uncontrolled variable
that resulted in different phenotypes [22, 23]. Future stud-
ies should address these differences.
In our studies we observed that Nlrp12−/− mice demon-
strated more severe course of EAE according to classical
evaluation of clinical scores, while in the work by Lukens
and co-workers, the authors noted appearances of the
atypical EAE. These results are intriguing, as overall effect
of Nlrp12 on the EAE pathology was similar to our obser-
vations. Furthermore, EAE is a well-characterized and the
most widely used mouse model to study MS [13]. It
exhibits the main features of MS pathology such as in-
flammation, destruction of myelin, and reactive gliosis.
Moreover, many of the current therapies for MS, such as
Tysabri were developed following EAE studies [24]. How-
ever, it is important to note that the evaluations of clinical
scores are subjective. In our studies, we did not measure
the degree of atypical EAE as there is no quantifiable scale
to evaluate this pathology. Observing video clips published
by Lukens et al. (supplemental materials), we can tell that
Nlrp12 mouse was severely compromised and had im-
paired righting reflex, which suggests severe weakness/
paralysis of the hind limbs as well as paralysis of the trunk
muscles.
To further elucidate how Nlrp12 is playing a protective
role in the disease, the spinal cords of both the WT and
Nlrp12−/− mice were analyzed for the expression of genes
implicated in EAE as well as in MS. Our results demon-
strated a significant increase in the mRNA expression of
Cox-2, IL-1β, and Ccr5 genes in the Nlrp12−/− mice com-
pared to the WT mice, suggesting a protective role played
by Nlrp12 in EAE at the level of pro-inflammatory gene ex-
pression. The increase in expression of pro-inflammatory
molecules in Nlrp12-deficient phenotype has been demon-
strated by multiple studies [22, 25].
Next, we demonstrated that Nlrp12 inhibits inflamma-
tion during EAE at the level of microglia. We showed that
Nlrp12 deficiency augments pro-inflammatory microglial
phenotypes by using purified primary microglia cells from
the WT and Nlrp12−/− mice. Consistent with our in vivo
observation, stimulation of microglia with LPS resulted in
a significant increase of iNOS expression, NO, TNFα, and
IL-6 secretion from the Nlrp12−/− microglia cells com-
pared to the WT microglia. These results are consistent
with the suppressive role of Nlrp12 in cells of myeloid ori-
gin [26]. A report by Lukens et al. also found increased in-

























Fig. 9 Nlrp12 deficiency augments expression of pro-inflammatory
molecules in the CNS after EAE. Results indicate fold change in
mRNA expression of pro-inflammatory proteins in the spinal cords of
the Nlrp12−/− mice relative to the WT mice. A significant increase in
the expression of Cox2, IL-1β, and Ccr5 mRNAs and no in the expression
of Mip3α were observed. Results are expressed as mean ± SD. Statistical
significance was accepted at *P < 0.05. Statistical analysis was done
using one-way ANOVA followed by Dunet comparison test relative to
control. n = 5
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Fig. 11 TNF-α and IL-6 concentrations following treatment with LPS in primary microglia cells. Microglia cells (1 × 105) from the Nlrp12−/− and
WT mice were stimulated with 500 ng/mL LPS for 12 h. a ELISA for TNF-α concentration. b ELISA for IL-6 concentration. Results are expressed as
mean ± SD. Statistical significance was accepted at *P < 0.05. Statistical analysis was done using one-way ANOVA followed by Tukey-Kramer
multiple comparison test. n = 5
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Fig. 10 Expression of iNOS in primary microglia cells. Microglia cells (1 × 105) from the Nlrp12−/− mice and WT mice were stimulated with 1 ug/mL LPS
for 12 h. a Western blot analysis. b Densitometric analysis of iNOS. c Concentration of nitrates using Griess reagent assay. Results are expressed as
mean ± SD. Statistical significance was accepted at *P < 0.05. Statistical analysis was done using one-way ANOVA followed by Tukey-Kramer multiple
comparison test. n = 5
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compared to WT controls, although, microglia responses
per se were not verified. Furthermore, the notion of in-
hibitory NLRs is not new. Similar to our results, stimula-
tion of primary Nlrx1−/− microglia cells revealed a
significant increase in the pro-inflammatory response,
thus, showing a suppressive role for Nlrx1 in microglial
activation [27].
The roles of microglia and astrocytes are well defined
in the pathology of MS. Previous studies on Nlrp3 have
demonstrated that the absence of this receptor results in
better disease outcome and reduced gliosis following
EAE [28]. The spinal cords of the Nlrp12−/− mice and
WT mice were stained with Iba1 and GFAP in order to as-
sess the extent of microgliosis and astrogliosis, respectively.
Surprisingly, no differences in the percentage of gliosis were
observed between the two genotypes at the third week;
however, after 9 weeks, the Nlrp12−/− mice demonstrated
significantly increased gliosis compared to the WT mice.
Additionally, in both genotypes, the majority of gliosis oc-
curs within the white matter area of the spinal cord. Al-
though a quantitative difference was not observed at the
third week, in vitro study suggests qualitative changes in
microglia activation. Indeed upon LPS stimulation, micro-
glia from the Nlrp12−/− mice released significantly more
pro-inflammatory mediators. Furthermore, the remarkable
increase in Ccr5 mRNA expression observed in the
Nlrp12−/− mice suggests that Nlrp12 may be playing a cru-
cial role in the influx of inflammatory infiltrates. CCR5 is
a chemokine receptor that is expressed primarily by
monocytes, macrophages, effector T cells, immature den-
dritic cells, and NK cells [29]. Moreover, previous studies
in both animal and in MS patients have demonstrated the
upregulation of CCR5 in inflammatory lesions [30–32].
Also, a chronic over-expression of IL-1β has been shown
to result in the disruption of the blood-brain barrier (BBB)
and in the infiltration of leukocytes such as macrophages,
DCs, and neutrophils [33, 34]. Thus, the increase of Ccr5
and IL-1β mRNA in the spinal cords of the Nlrp12−/−
compared to the WT mice during EAE supports the no-
tion of an increased influx of inflammatory cells in these
mice. In fact, the entry of pro-inflammatory leukocytes
into the CNS is an early phenomenon capable of initiat-
ing events that result in BBB disruption and neuroin-
flammation [35]. Interestingly, previous studies have
demonstrated a reduction in inflammatory infiltrates
within the CNS in EAE-induced Nlrp3−/− mice, where
Nlrp3 was shown to play an inflammatory role by indu-
cing immune cell migration whereas, our results suggest
that Nlrp12 plays a protective role by maintaining the
level of inflammatory influx [36, 37]. Thus, future stud-
ies should focus on evaluating in details the presence of
inflammatory infiltrates in order to clarify the driving
force responsible for the differences observed between
WT and Nlrp12−/− mice.
Conclusion
The study of NLRs and their functions has been mainly
studied in the context of host and pathogen interactions.
Their role in mediating the inflammatory response is
well recognized, while their role in other diseases is an
emerging field. Recent reports suggest that Nlrs may
play a detrimental as well as beneficial role in the pro-
gression of EAE. For example, Nod1, Nod2, and Nlrp3
augment inflammation and T cell responses that lead to
increased EAE severity. On the other hand, the expres-
sion of Nlrp12 and Nlrx1 inhibits the expression of pro-
inflammatory genes, suppressing inflammation and
reducing the severity of EAE [27]. In many neurodegen-
erative diseases the regulation of neuro-inflammatory re-
sponses is a key target for therapeutic interventions.
Numerous studies have focused on the role and contri-
bution of T- and B-lymphocytic responses in MS, and
much of the pathophysiology of MS has gravitated
around the adaptive branch of the immune system. The
implication of the adaptive immune response is undeni-
able in this disorder, given that the primary cause of
damages in the nervous system of MS patients is due to
CNS inflammation, where CD4+ autoreactive T cells pri-
marily react to myelin epitope, enter the CNS, and result
in the destruction of myelin [3]. At this stage, we are not
excluding the role of Nlrp12 in T cell responses during
EAE. However, it is vital to understand the underlying
cause of the inflammatory process in MS. Thus, it is im-
portant to focus on the innate immune response, since
in essence, inflammation is a response of innate immun-
ity [38]. Thus our findings that Nlrp12 plays a role in
microglia activation during EAE may help find the
mechanism that regulates CNS specific inflammation.
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